Treatment of autoimmune hepatitits according to the national, international recommendations and own experience
Journal Title: Гастроентерологія - Year 2018, Vol 52, Issue 4
Abstract
Autoimmune hepatitis (AIH) is rare liver pathology, but there is the increase in the number of patients over the last years. There is no unambiguous determination or clear pathognomonic criteria of AIH. A presence of autoantibodies, hypergammaglobulinemia, characteristic morphological changes and response to immunosuppressive therapy are inherent for AIH. Immunosupressive therapy must provide the control of autoimmune process, elimination of inflammatory syndrome, fibrosis reduction, slowing down the development of cirrhosis. The first-line drugs in AIH are corticosteroids and azathioprine, more effective than placebo. Prednisolone is prescribed at a dose of 40–60 mg/day, individual dose is 0.5–1 mg/kg/day. The higher the activity of cytolysis, the larger the required dose of prednisolone. When cytolysis is reduced according to hepatic tests, the dose of prednisolone is decreased. Methylprednisolone is used more often in practice. Azathioprine is administered either immediately or 2 weeks after prednisolone at a dose 50 mg/day with a possible increase to 100 mg/day, individual dose is 1–2 mg/kg/day. Now preference is given to combination therapy with prednisolone and azathioprine. Assessment of the effectiveness of AIH treatment involves monitoring the level of aminotransferases and immunoglobulin G, their complete normalization is desirable. To evaluate fibrosis, we used liver elastography. Treatment is actually life long. The second-line drugs are mycophenolate mofetil, cyclosporine, tacrolimus, sirolimus, everolimus and other. The mycophenolate mofetil is considered most studied. The search for effective AIG therapy continues, methods of cellular, anticytokine, antifibrotic therapies are being developed. Clinical examples from own experience are presented. Treatment of AIH is a difficult process. Modern recommendations, data from the studies and accumulated experience help considerably. The choice of therapy requires individual approach, taking into account the features of clinical course and response to therapy.
Authors and Affiliations
Yu. M. Stepanov, S. V. Kosynska
Keywords
Related Articles
- EP ID EP440852
- DOI 10.22141/2308-2097.52.4.2018.154146
- Views 78
- Downloads 0
The feasibility of using ursodeoxycholic acid in the treatment of patients with non-alcoholic fatty liver disease: a clinical case
Non-alcoholic fatty liver disease (NAFLD) is on a leading position among chronic liver diseases. In addition, the pathogenesis of NAFLD has not been fully studied for today. Some authors suggest that NAFLD is one of the...
Taurin and its secrets in experimental hepatology
Taurine is a unique amino acid. It has various biological effects aimed at maintaining physiological homeostasis, including antioxidation, modulation of ion transport, osmoregulation, regulation of neurotransmitters and...
Digestive system diseases: the actual problem of clinical medicine
Background. Worldwide, the number of people suffering from gastrointestinal and hepatobiliary diseases is increasing annually, and, therefore, they need specialized gastroenterological assistance. The objective is to id...
Place of Needle Biopsy in the Diagnosis of Chronic Diffuse Liver Diseases
The article deals with the diagnosis of chronic diffuse liver diseases. A brief review of noninvasive methods of diagnosis of liver fibrosis and percutaneous liver biopsy is given. A comparison has been carried out betwe...
ANGIODYSPLASIA OF THE SMALL INTESTINE — A RARE CAUSE OF OCCULT GASTROINTESTINAL BLEEDING
The review of literature shows the causes of occult gastrointestinal bleeding, and reports the role of angiodysplasias (arteriovenous malformations) in their development. There are presented results of own research — ide...